Bioanalytical Services for Stroke Drugs

Bioanalysis is commonly used to characterize the quantitative measurement of compounds (drugs) or their metabolites in biological fluids (mainly blood, plasma, serum, urine, or tissue extracts). It plays a vital role in drug development and biomarker discovery, helping to develop safer and more effective drugs while reducing development time and costs. Bioanalysis is involved in all stages of a compound's development from the time of discovery through drug development to a component of pharmacokinetic/pharmacodynamic characterization for market authorization.

Fig. 1. Possible scenario of bioanalysis in discovering drugs. Fig. 1. Possible scenario of bioanalysis in discovering drugs. (Pandey et al., 2010)

Custom Bioanalytical Services

Ace Therapeutics has an experienced team and a bioanalytical laboratory equipped with state-of-the-art instrumentation. We offer bioanalytical services customized to your company's program goals to support stroke drug development. Our bioanalytical services can support the stroke drug discovery phase from lead compound confirmation and lead compound optimization to preclinical studies.

From method development and characterization, bioanalytical sample preparation, to assay optimization, our laboratories are equipped with state-of-the-art technology platforms (e.g., LC-MS/MS, qPCR, ion-pair reversed-phase (IP-RP)). We work to the highest standards, providing testing suitable for stroke discovery and research.

Bioanalytical Services for Small Molecule Drugs for Stroke

We provide comprehensive global bioanalytical support for stroke drugs discovery programs from discovery through preclinical development. Our team can perform bioanalytical services for small molecules for stroke by quantitatively measuring drug compounds and/or their metabolites in various biological matrices with high precision.

Bioanalytical Services for Therapeutic Antibodies for Stroke

We offer a comprehensive range of analytical services to meet the needs of therapeutic antibodies development for stroke in terms of pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity/immunoreactivity, toxicokinetics (TK), and various types of biomarkers.

Bioanalytical Services for Cell and Gene Therapy for Stroke

Efficient and effective development of assays to characterize cell and gene therapy products is critical to stroke drug discovery programs. We can identify and quantify analytes at the gene and protein level, including analysis of viral vectors, oligonucleotides, siRNA/miRNAs, stem cell products, and gene therapy products. These data support PK/TK studies, efficacy studies, safety assessments, and immunogenicity studies.

Our Advantages

  • Our highly trained and skilled bioanalytical team works closely with you to design customized studies that meet your specific goals.
  • Our high-throughput technology platform provides in vitro/in vivo ADME, PK/TK, PD, and biomarker and metabolite analysis to support your stroke drugs development.

Ace Therapeutics can work with you to develop LC/MS assays for stroke drug development to meet your bioanalytical needs. Our team of experts can help you design and conduct validated assays to move your stroke drug discovery and development program forward. If you are interested in our services, please do not hesitate to contact us!

  1. Pandey, S., et al. (2010). Bioanalysis in drug discovery and development. Pharmaceutical methods, 1(1), 14-24.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket